Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma

Benjamin S Gerendash1
Patricia A Creel2

1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, 2Oncology, Clinical Operations, Duke University Medical Center, Durham, NC, USA

Abstract: Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renal-cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC, cabozantinib was associated with a significant improvement in overall survival, progression-free survival, and antitumor response compared with everolimus. Adverse events (AEs) were common for patients receiving cabozantinib, but were effectively managed with supportive care and dose modifications, as discontinuations of cabozantinib due to an AE were infrequent. This article reviews the management of the more common AEs associated with cabozantinib based on findings from the pivotal study, clinical practice guidelines, and the authors’ real-world clinical experience, with support from published literature. We focus on hypertension, palmar–plantar erythrodysesthesia, diarrhea, nausea, vomiting, decreased appetite, fatigue, and stomatitis. Effective management of these AEs involves a multimodal strategy that includes patient education, prophylactic and supportive care, and dose modifications. Effective AE management can allow patients to maintain antitumor activity with cabozantinib while mitigating the impact on quality of life.

Keywords: cabozantinib, adverse-event management, renal-cell carcinoma, targeted therapy, tyrosine-kinase inhibitors

Introduction

In the US, an estimated 64,000 new cases of kidney cancer will be diagnosed in 2017, primarily composed of clear-cell renal-cell carcinoma (RCC).1 Until as recently as 2006, treatments for advanced RCC were limited to cytokines, including IFNα and IL2. These therapies were associated with considerable toxicity and showed limited efficacy.2 This led to the development of therapies, including tyrosine-kinase inhibitors (TKIs), that target the VEGF pathway, which drives angiogenesis and tumor growth.3–5 Clinical studies have demonstrated that sequential use of VEGF-pathway inhibitors is a feasible and effective approach to treatment,6–8 and is supported in treatment guidelines.9–11

In 2016, the TKI cabozantinib was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of patients with advanced clear-cell RCC who have received prior antiangiogenic therapy, and became a preferred second-line option for RCC in US and European treatment guidelines.9–13 Cabozantinib maintains VEGF-pathway inhibition but also targets MET and AXL, receptor tyrosine kinases that are overexpressed in RCC14–16 and have been shown to promote tumor-cell survival and resistance to VEGF-pathway inhibition.17–20 Approval of cabozantinib in
RCC was based on efficacy and safety results from the Phase III METEOR study, where it improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) compared with everolimus in patients who had received prior antiangiogenic therapy. The safety and tolerability profile of cabozantinib was manageable: the majority of patients required dose modifications, but treatment discontinuations due to adverse events (AEs) were infrequent.

Given the recent approval of cabozantinib for RCC, it is timely to discuss strategies to manage the more common AEs associated with cabozantinib. In this article, we review the clinical outcomes from the pivotal Phase III METEOR trial and provide practical guidance to prepare patients for cabozantinib therapy. We propose management approaches for the more common AEs based on guidelines from cancer organizations, the literature on managing AEs associated with TKIs, and our own clinical experience.

**Cabozantinib for the treatment of advanced RCC**

Cabozantinib (Cabometyx®; Exelixis Inc., South San Francisco, CA, USA), is approved for patients with advanced clear-cell RCC who have received prior treatment with an antiangiogenic therapy, and is formulated as tablets with a starting dose of 60 mg daily. Three tablet strengths (20 mg, 40 mg, and 60 mg) provide clinicians with the flexibility to modify doses. Cabozantinib is also approved for progressive, metastatic medullary thyroid cancer, but is formulated as a capsule (Cometriq®, Exelixis Inc.) with a starting dose of 140 mg once daily. Importantly, the tablet and capsule formulations are not bioequivalent and not interchangeable.

**METEOR, a randomized Phase III open-label trial in advanced RCC**

In the pivotal Phase III, open-label METEOR study, 658 patients with advanced clear-cell RCC and at least one prior VEGFR-targeted therapy were randomized to receive 60 mg of cabozantinib or 10 mg of everolimus daily, an approved second-line therapy for advanced RCC. Cabozantinib was associated with significant improvement in all three key efficacy parameters: the primary end point of PFS and the key secondary end points of ORR and OS. In the overall study population, median PFS was 7.4 months for cabozantinib versus 3.9 months for everolimus (HR 0.51, 95% CI 0.41–0.62; P<0.0001), and ORR by independent radiological review was 17% versus 3% (P<0.0001). Median OS was 21.4 months for cabozantinib versus 16.5 months for everolimus (HR 0.66, 95% CI 0.53–0.83; P=0.00026). PFS and OS benefits with cabozantinib were observed across all studied subgroups, including those defined by prior therapy, metastatic site, and tumor burden.

During METEOR, there were no unexpected types or rates of treatment-emergent AEs in the cabozantinib arm, and safety data were comparable between the initial data cutoff for PFS (May 22, 2015) and the later cutoff for OS (December 31, 2015). For consistency in this review, we discuss results from the May 22, 2015 cutoff in the overall study population, as the majority of safety analyses reported were with this data set, including the product label. The most frequent AEs of any grade in the cabozantinib arm were diarrhea (74%), fatigue (56%), nausea (50%), decreased appetite (46%), palmar–plantar erythrodysesthesia syndrome (PPES) (42%), hypertension (37%), vomiting (32%), decreased weight (31%), constipation (25%), dysgeusia (24%), and stomatitis (22%). Generally, these AEs were grade 1 or 2 in severity and occurred early on during treatment. Median time to onset for hypertension, PPES, and diarrhea of any grade was less than 5 weeks from the start of treatment.

During the METEOR study, dose interruptions and reductions were common with cabozantinib, but effective. Dose reductions were reported for 60% of patients receiving cabozantinib, resulting in a median average daily dose of 44 mg, but only 9% of patients discontinued cabozantinib due to an AE. The most common AEs leading to cabozantinib dose reductions were diarrhea (16%), PPES (11%), fatigue (10%), and hypertension (8%). Dose modifications of cabozantinib were implemented early on, with median time to first dose interruption of 38 days and median time to first dose reduction of 55 days.

Although this review focuses on managing more common AEs, health-care providers should be knowledgeable of cabozantinib’s overall safety profile, including rare but serious AEs. These include hemorrhage, gastrointestinal (GI) perforations, fistulas, thrombotic events, and reversible posterior leukoencephalopathy syndrome. During METEOR, rates for grade ≥3 events were 3.6% for venous and mixed/unspecified thrombotic events, 2.1% for hemorrhage, and <1% for GI perforations and fistulas. There were no reversible posterior leukoencephalopathy-syndrome events.

Overall, the safety and tolerability profile of cabozantinib was consistent with that of other TKIs approved for RCC. Dose reductions are not uncommon among TKIs, because of interpatient pharmacokinetic variability. The cabozantinib dose should be tailored to the maximum
Managing adverse events associated with cabozantinib

tolerable level for the individual patient, along with prophylactic and supportive-care measures.

**Cabozantinib dose modifications**

The cabozantinib label provides a dosing algorithm to resolve AEs based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading scale (Figure 2).\(^1\)\(^2\)\(^3\)\(^4\) Cabozantinib should be withheld for grade 4 events, and can be restarted after resolution to grade 1, with daily dose reduced by 20 mg. This approach is also recommended for grade 3 or intolerable grade 2 events that cannot be managed with supportive care or dose reduction. If the patient previously received 20 mg, then the dose should be resumed at 20 mg, as tolerated, or if necessary discontinued.

Cabozantinib is metabolized mainly by CYP3A4, so CYP3A4 inhibitors and inducers should be avoided if possible.\(^1\)\(^2\)\(^3\)\(^4\) Strong CYP3A4 inhibitors include clarithromycin, telithromycin, conivaptan, grapefruit juice, protease inhibitors, antifungal azoles, and nefazodone. Strong CYP3A4 inducers include rifampin, phenytoin, carbamazepine, phenobarbital, rifabutin, rifapentine, and St John’s Wort. If a patient requires concomitant treatment with a strong CYP3A4 inhibitor, the cabozantinib dose should be reduced by 20 mg. If the CYP3A4 inhibitor is discontinued, the prior dose should be resumed after an appropriate washout period. Conversely, the cabozantinib dose should be increased by 20 mg if a patient requires concomitant treatment with a strong CYP3A4 inducer. The daily cabozantinib dose should not exceed 80 mg, and if a CYP3A4 inducer is discontinued, the prior cabozantinib dose should be resumed after an appropriate washout period.

**AE-management strategies**

Before cabozantinib treatment begins, it is important to evaluate the overall health of a patient and provide appropriate education related to therapy, including risk of AEs.\(^9\)\(^3\) Although previously treated patients may be familiar with AEs associated with TKIs, some are relatively unique to specific TKIs, and individual patients can experience different AEs with different TKIs.\(^2\)\(^4\)\(^2\)\(^5\)\(^3\)\(^4\) With each new treatment, it is important to educate and assess a patient’s understanding and implementation of AE management.

It is important to obtain a detailed medical history, including comorbidities, concomitant therapies, and baseline vital and laboratory assessments, including baseline blood...
pressure (BP) and liver-function tests. It is helpful for patients routinely to record vital signs and dietary intake and notify their health-care providers of any changes. Also, patients should be instructed to avoid eating for at least 2 hours before and at least 1 hour after taking cabozantinib, as food can affect its bioavailability.

In subsequent sections, we discuss the more common AEs experienced by patients receiving cabozantinib during the METEOR trial and practical prophylactic and supportive-care measures, including those provided on the label, in the published literature, and our own clinical experience. These include hypertension, PPES, diarrhea, nausea and vomiting, decreased appetite, fatigue, and stomatitis. Many of the recommendations are derived from guidelines of oncology societies, including the American Cancer Society, National Comprehensive Cancer Network, Oncology Nursing Society, and European Society of Medical Oncology.

### Hypertension

Hypertension is a common AE associated with therapies targeting the VEGF pathway. Elevation in BP may be caused by increasing vascular tone secondary to reduced nitric oxide levels, as well as vascular resistance from endothelial-cell dysfunction and damage. In METEOR, 22% of patients experienced grade 1–2 hypertension and 15% experienced grade 3; no grade 4 events were reported (Figure 3). The median time to onset of hypertension was 3 weeks.

Because hypertension has an early onset, patients and/or their caretakers should be encouraged to keep a record with home BP monitoring, taking BP measurements prior to starting cabozantinib and routinely during treatment.

### Figure 2 Cabozantinib-dosing algorithm.

Notes: *For patients with mild–moderate hepatic impairment or for patients requiring concomitant treatment with a strong CYP3A4 inhibitor, reduce starting dose to 40 mg. For patients requiring concomitant treatment with a strong CYP3A4 inducer, increase starting dose to 80 mg. Data from these studies.*

Abbreviations: AEs, adverse events; GI, gastrointestinal; RPLS, reversible posterior leukoencephalopathy syndrome.
inhibitor, or angiotensin-receptor blocker (Table 1). The BP goal is <150/90 mmHg for patients older than 60 years and <140/90 mmHg for younger patients. If target BP is not reached, the dose of antihypertensive medication can be increased or a second medication added, although ACE inhibitors and angiotensin-receptor blockers should not be combined. Renin–angiotensin inhibitors or CCBs may be preferred over thiazide diuretics to reduce electrolyte loss and risk of QT prolongation. However, caution should be taken when selecting a CCB, as some agents can be potent CYP3A4 inhibitors; as detailed earlier, the cabozantinib dose should be reduced by 20 mg when used concomitantly with a strong CYP3A4 inhibitor. Studies indicate that early (rather than delayed) antihypertensive treatment is more effective, and that early combination of antihypertensive treatments is more effective than dose escalation of a single agent.

For persistent hypertension despite optimized antihypertensive therapy, the cabozantinib dose should be withheld and/or reduced as indicated. Cabozantinib should be discontinued for hypertensive crisis or if severe hypertension (≥160/100 mmHg) persists despite supportive interventions.

### Palmar–plantar erythrodysesthesia syndrome

During METEOR, 34% of patients experienced grade 1–2 PPES, and 8% experienced grade 3 (Figure 3). Median onset to the first PPES event was 3.4 weeks (Figure 1). Manifestations of PPES with cabozantinib include tingling, numbness, slight redness, mild hyperkeratosis, pain, and symmetrical red and swollen areas on palms and soles. Although PPES is not life-threatening and patients may present with mild–moderate skin changes, it can develop into a painful condition that limits activities of daily living and significantly impacts quality of life.

Examples of typical PPES events associated with cabozantinib are shown in Figure 4. Although there is overlap among the TKIs in the presentation of PPES, the location and severity of these events vary.

---

**Figure 3** Common AEs experienced by patients in the cabozantinib arm of the METEOR study (safety-analysis set, n=331). There were no grade 3 events for hypertension, diarrhea, vomiting, stomatitis, or decreased appetite. Grade 3 is the most severe grade for PPES, fatigue, and nausea. Individual icons reproduced from the Noun Project (<https://thenounproject.com>).

**Abbreviations:** ADL, activities of daily living; AE, adverse event; BP, blood pressure; Gr, grade; TPN, total parenteral nutrition; PPES, palmar–plantar erythrodysesthesia syndrome; WNL, within normal limits.
appearances of cutaneous abnormalities with cabozantinib can manifest differently from other TKIs in our clinical experience. For instance, the lateral sides of fingers or periungual zones may be affected in patients receiving cabozantinib. In a patient who was a professional writer, the callused areas from the knuckles of his writing hand developed PPES. Studies of cabozantinib treatment in solid tumors have described other dermatologic events to be monitored, including generalized pigment

Table 1 Summary of prophylactic and supportive-care strategies for patients treated with cabozantinib

| Hypertension | Prophylactic |
|--------------|-------------|
| - Assess pretreatment risk with >2 BP measurements, thorough patient history, physical examination, lab evaluation; monitor BP routinely | |
| - Establish a home BP-monitoring plan | |
| Supportive |
| - Initial treatment with a CCB, ACEi, ARB, or thiazide diuretic |
| - ACEIs, ARBs, or CCBs may be preferred over thiazide diuretics to reduce electrolyte loss and risk of QT prolongation |
| - Thiazide diuretics and CCBs are preferred for black patients |
| - Provide up to three standard antihypertensive agents, but do not combine ACEIs and ARBs |
| - Avoid CYP3A4 inhibitor/inducers (eg, verapamil, diltiazem) |

| PPES and other cutaneous AE s | Prophylactic |
|-----------------------------|-------------|
| - Remove hyperkeratotic areas (ie, calluses) |
| - Instruct patients to protect extremities from hot water, pressure, friction |
| - Instruct patients to use hypoallergenic skin moisturizers containing colloidal oatmeal, sunscreen with SPF > 30, thick cotton gloves/socks, gel shoe inserts |
| Supportive |
| - Instruct patients to use urea-, salicylic acid-, and/or corticosteroid-containing creams |
| - Patients may apply medical-grade skin adhesive (eg, Dermabond® Topical Skin Adhesive) to cracked and painful regions |
| - Provide topical (eg, 10 mg morphine, 2%–4% lidocaine) or oral analgesics (NSAIDs, GABA) |
| - Pyridoxine (vitamin B6) is not recommended |

| Diarrhea | Prophylactic |
|----------|-------------|
| - Instruct patients to log food and water intake, review with patients regularly |
| - Limit/avoid foods that could cause gastrointestinal events: lactose products for those lactose-intolerant, high-fat foods, salt/cured/pickled/smoked foods |
| Supportive |
| - Administer standard antidiarrheal treatments (eg, loperamide as needed); more than one agent may be necessary |
| - Instruct patients to maintain hydration levels, consume frequent small meals, avoid high-fat foods and alcohol |
| - Avoid foods high in insoluble fiber (eg, nuts, seeds, beans), sugar-free products |
| - BRAT diet: bananas, rice, apple sauce, and toast |
| - Clean and dry the rectal area with mild soap and water (eg, sitz baths), and use disposable wipes and a moisture-barrier ointment |

| Nausea/vomiting | Prophylactic |
|-----------------|-------------|
| - Antiemetics may be provided prophylactically |
| - Chocolate, caffeine, alcohol, and nicotine should be avoided |
| Supportive |
| - 5-HT3 antagonists are recommended over the use of NK1-receptor antagonists, dexamethasone, or nabilone to avoid CYP3A4 modulation |
| - Consider guidelines for GERD, including lifestyle and dietary modifications and the use of proton-pump inhibitors |
| - Histamine H2-receptor antagonists may also provide relief as a maintenance option or for those with refractory symptoms |

| Decreased appetite | Prophylactic |
|--------------------|-------------|
| - Encourage patients to consume nutritious, high-calorie, high-protein foods, and to snack throughout the day (eg, eggs, poultry, fish, honey, cheese, gelatin) |
| - Limit/avoid foods that could cause gastrointestinal events |
| - Routinely query patient and caregivers on diet and appetite |
| Supportive |
| - Administer progestins (eg, megestrol acetate) or other appetite stimulants (eg, dronabinol) |

| Fatigue | Prophylactic |
|---------|-------------|
| - Establish baseline fatigue levels and discuss grading scales with patients |
| - Encourage patients to conduct relaxing activities, rest often, exercise with aerobic activity, or resistance training for appropriate patients |
| Supportive |
| - Rule out common causes, including but not limited to disease-specific morbidities, hypothyroidism, anemia, deconditioning, emotional distress, nutrition, and sleep disturbances |
| - Consider psychostimulants (eg, methylphenidate; avoid modafinil, as it may increase cabozantinib exposure) |

(Continued)
Table 1 (Continued)

| Stomatitis                  | Prophylactic                                                                 |
|-----------------------------|-------------------------------------------------------------------------------|
|                             | • Comprehensive dental exam and treatment, replacement, or removal of ill-fitting dentures |
|                             | • Instruct patients to protect their oral cavity from irritation by avoiding hot, salty, spicy, and acidic foods; instead, consume soft foods cut into small pieces, use straws, and avoid tobacco and alcohol |
|                             | • Instruct patients, including those with dentures, to conduct regular, gentle oral hygiene (eg, use pediatric toothpaste, soft toothbrushes, flossing, oral rinses) |
|                             | • Avoid oral rinses with alcohol, as these can exacerbate dry mouth |
|                             | Supportive                                                                    |
|                             | • Avoid spicy, sticky, and other foods that could irritate (crackers, citrus fruits, pickles, raw vegetables) |
|                             | • Administer “magic” mouthwash containing equal parts of 2% viscous lidocaine, diphenhydramine, bismuth subsalicylate, or aluminum/magnesium hydroxide; or palliative rinses (eg, Biotène® Dry Mouth Oral Rinse, salt water, sodium bicarbonate containing mouthwash) |

Abbreviations: ACeI, ACE inhibitor; AE, adverse event; ARB, angiotensin-receptor blocker; BP, blood pressure; CCB, calcium-channel blocker; GABA, γ-aminobutyric acid; GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory drug; PPES, palmar–plantar erythrodysesthesia syndrome; SPF, sun-protection factor.

Dilution, hair depigmentation, xerosis, scrotal erythema/ulceration, and subungual nail-splinter hemorrhages. Given the potential for dermatologic AEs, a full skin and nail assessment should be conducted before starting cabozantinib, with routine evaluation during treatment.

Prophylactic strategies to prevent dermatologic AEs are aimed at treating existing skin abnormalities (eg, calluses, skin disorders), protecting the skin, reducing friction to hands and feet, and maintaining skin moisture (Table 1). If needed, supportive treatments include topical interventions (corticosteroids, keratolytics, moisturizers, and analgesics).

For the aforementioned patient who was a writer, PPES resolved with the use of cotton gloves and 20% urea cream. Dose reduction usually ameliorates dermatologic AEs that cannot be managed with supportive care.

Diarrhea

Although TKIs are associated with diarrhea, the underlying pathogenesis is not well understood. During METEOR, 63% of patients in the cabozantinib arm experienced grade 1–2 diarrhea and 11% experienced grade 3; there were no grade 4 events (Figure 3). The median onset of diarrhea was 2 days.

Figure 4 Examples of palmar–plantar erythrodysesthesia syndrome resulting from treatment with cabozantinib in patients with solid tumors.

Notes: Erythema, hyperkeratosis, and callus formation at sites of friction of hands (A) and feet (B). Bullae, hyperkeratosis, and erythema on medial surface (C) and plantar surface (D) of feet. Republished with permission of Dove Medical Press, from The treatment landscape in thyroid cancer: a focus on cabozantinib, Weitzman SP, Cabanillas ME, Volume 7, 2015; permission conveyed through Copyright Clearance Center, Inc. C and D Reproduced with permission from JAMA Dermatology, 2015, Volume 151 (Issue 2): pages 170–177. Copyright © 2015 American Medical Association. All rights reserved.
4.9 weeks, and diarrhea was the commonest reason for dose reductions with cabozantinib (16%).

To decrease the risk of developing diarrhea, patients should be encouraged to maintain hydration, consume small and frequent meals, and avoid lactose-containing products, high-fat foods, and alcohol. Patients should log their dietary intake to help identify and remedy potential non-treatment causes of diarrhea. Uncomplicated diarrhea often can be managed by replacement of fluids and electrolytes, self-administration of antidiarrheal medications (eg, loperamide and octreotide), and diet modifications (Table 1). Patients should be advised to clean and dry the anal area with mild soap and water, use disposable wipes, and apply a moisture-barrier ointment. Patients experiencing intolerable diarrhea of grade 2 despite supportive measures or grade 3 diarrhea should have their cabozantinib dose withheld until improvement to grade ≤1, and the dose should be reduced upon resuming treatment. However, providers should ensure that patients understand and are implementing antidiarrheal strategies before any dose modification.

Nausea and vomiting
Grade 1–2 nausea (46%) and vomiting (30%) were common among patients in the cabozantinib arm of METEOR, but grade 3 events were infrequent (4% and 2%, respectively; Figure 3). Antiemetics can be provided as prophylaxis or at the first sign of nausea and vomiting. 5-HT₃-receptor antagonists, such as ondansetron, are recommended over the use of NK₁-receptor antagonists and dexamethasone, because the latter agents can modulate CYP3A4. The cannabinoid nabixim is a weak inhibitor of CYP3A4. We typically evaluate and treat for gastroesophageal reflux disease when a patient complains of nausea. Guidelines for gastroesophageal reflux disease recommend lifestyle and dietary modifications and the use of proton-pump inhibitors. Histamine H₂-receptor antagonists may also provide relief as a maintenance option or to those with refractory symptoms. Head-of-bed elevation and refraining from eating 2–3 hours prior to bedtime may also provide overnight relief. In terms of diet, simple foods (eg, rice, noodles, skinless chicken or turkey) may be better tolerated by patients, and chocolate, caffeine, alcohol, and nicotine should be avoided.

If vomiting does develop, patients should rinse their mouth and delay food intake until the nausea subsides.

Decreased appetite
Patients treated with cabozantinib may experience decreased appetite. Decreased appetite of grade 1–2 affected 44% of cabozantinib-treated patients during METEOR, and 2% experienced grade 3 (Figure 3). In our experience, decreased appetite can occur with or without GI-related AEs. Although decreased appetite may appear benign, it is important for patients to continue high-calorie, high-protein nutrition during therapy to maintain lean body mass in light of a potential correlation with prognosis. To overcome the challenge of consuming food in the absence of appetite, we encourage patients to partake in high-calorie, appetizing foods (eg, ice cream or nonfat frozen yogurt) that do not result in GI complications. Snacks could include nutrition bars and supplemental shakes.

Appetite-stimulating medication, such as dronabinol, can be provided prophylactically and as supportive care for appropriate patients (Table 1). We recommend starting appetite-stimulating medication at the lowest dose and titrating to effect while monitoring for AEs.

Fatigue
Fatigue is one of the more frequent AEs experienced by patients with RCC receiving TKI therapy, and may be severe enough to require dose reduction or even discontinuation. It is important to recognize and appropriately manage this common, yet often underdiagnosed AE, and to note that fatigue can have multiple causes that should be considered part of the differential diagnosis, including disease-specific morbidities, hypothyroidism, anemia, deconditioning, sleep disturbances, alcohol/substance abuse, medications, emotional distress, and suboptimal diet and fluid intake. During METEOR, 47% of patients receiving cabozantinib experienced grade 1–2 fatigue, 9% experienced grade 3 (Figure 3), and 10% of patients required dose reductions to manage fatigue. Hypothyroidism was reported in 20% of patients receiving cabozantinib with no grade 3/4 events, and 17% of patients experienced anemia of any grade with a grade 3/4 rate of 5%.

There are few evidence-based interventions for ameliorating fatigue, so it is vital to establish baseline fatigue levels, educate patients for early recognition of symptom worsening, and routinely reevaluate patients. During treatment, patients should be encouraged to conduct relaxing activities and rest often. We advise daily light exercises (20–30 minutes), such as resistance training, walking, or yoga. Aerobic activity can ameliorate fatigue in some patients, and resistance training may attenuate cancer-related skeletal muscle wasting.

For patients with persistent fatigue without an etiology, pharmacologic management with psychostimulants, such as...
methylphenidate, may be appropriate. Modafinil should be avoided, because of its potential to reduce cabozantinib exposure (Table 1). Dose interruptions can be considered for grade 3 fatigue, particularly if it is part of a constellation of symptoms, and dose reduction should be considered if pharmacologic interventions do not reduce symptoms.

Stomatitis

Symptoms of stomatitis or oral mucositis secondary to TKI treatment often include dry mouth, oral sensitivity or soreness, and taste changes. There may not be obvious morphologic changes characteristic of chemotherapy-induced mucositis. Among cabozantinib-treated patients in METEOR, 20% experienced grade 1–2 stomatitis and 2% experienced grade 3 (Figure 3). Oral AEs have been shown to emerge early on with cabozantinib treatment, usually within the first few months.

Preventive measures are strongly recommended. A comprehensive dental exam and treatment prior to initiation of cabozantinib, along with replacement or removal of ill-fitting dentures, should be conducted to reduce the risk of developing stomatitis. During treatment, patients should routinely practice gentle oral-hygiene strategies, preferably after every meal, and adapt their diet to avoid irritating (eg, spicy or sticky) foods (Table 1).

In our clinical experience, grade 3 stomatitis results in dose interruption and usually dose reduction, whereas grade 1–2 levels can be managed without dose modification. Oral-care interventions aim to promote cleansing, moisture, and comfort, and can include “magic mouthwash” (equal parts 2% viscous lidocaine, diphenhydramine, bismuth subsalicylate, or aluminum/magnesium hydroxide) and swish-and-spit rinses, such as Biotène® Dry Mouth Oral Rinse, salt water, or sodium bicarbonate-containing mouthwash. Oral rinses with alcohol should be avoided, as these can exacerbate dry mouth.

Special considerations

Besides dose modifications for AE management, specific patient populations may also require dose adjustments of cabozantinib. Although no dose adjustment is recommended for patients 65 years of age or older, a lower cabozantinib starting dose may be appropriate for some elderly patients, particularly those who are frail with poor performance status and likely to require dose modification given the safety profile of cabozantinib. Patients with mild or moderate hepatic impairment should start with 40 mg once daily. Cabozantinib is not recommended for use in patients with severe hepatic impairment. The METEOR study protocol advised that patients with drug-related grade 2 elevated alanine transaminase, aspartate transaminase, or bilirubin lasting longer than 1 week have their cabozantinib dose reduced by 20 mg, and patients with grade ≥3 elevations have doses withheld until returning to grade ≤1 and then restarting cabozantinib at a reduced dose. Patients with mild–moderate renal impairment do not require dose modifications. Cabozantinib has not been studied in patients with severe renal impairment.

Patients with preexisting conditions that put them at greater risk of experiencing serious AEs should be monitored carefully. For example, patients with metastases located in the pulmonary or GI regions should be examined for risk of hemorrhages, perforations, and fistulas, particularly those with invasive metastases, concomitant use of anticoagulants, prior surgery, or a history of GI disorders (eg, diverticulitis, inflammatory bowel disease).

Conclusion

Cabozantinib has shown significant clinical benefit in the treatment of advanced clear-cell RCC, and has become a preferred standard of care for second-line treatment. Similarly to other targeted therapies, there is a need to anticipate and manage AEs to optimize treatment outcomes. Patients receiving cabozantinib should be educated on common AEs, prophylactic and symptomatic measures, and be routinely followed to provide timely and appropriate dose modifications and supportive care and monitor for rare, asymptomatic events. Effective AE management should help to mitigate the impact of AEs and allow patients to maintain extended treatment with cabozantinib. Further evidence, from both clinical experience and prospective trials, is needed to drive practice consensus and define optimal approaches for cabozantinib and other TKI therapies.

Acknowledgments

Medical writing and editorial assistance were provided by Christin Chong, PhD and Michael Raffin of Fishawack Communications (Conshohocken, PA). Funding for this work was provided by Exelixis Inc (South San Francisco, CA).

Author contributions

Both authors contributed to study conception/design, provision of study material/patients, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript.
Disclosure
BG has received honoraria from Exelixis, and PAC has received honoraria from Pfizer and Exelixis. The authors report no other conflicts of interest in this work.

References
1. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: ACS; 2017.
2. Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2016;5(2):169–181.
3. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028–1043.
4. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009;76(9):939–945.
5. Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1001–1017.
6. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1913–1939.
7. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823.
8. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927.
9. Motzer R, Jonasch E, Agarwal N, et al. NCCN guidelines: kidney cancer—version 2. 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed February 6, 2017.
10. Ljungberg B, Bensalah K, Bex A, et al. European Association of Urology guidelines: renal cell carcinoma. 2016. http://uroweb.org/guideline/renal-cell-carcinoma. Accessed February 20, 2017.
11. Escudier B, Porta C, Schmieder M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27 Suppl 5:v58–v68.
12. Cabometyx® (cabozantinib) [prescribing information]. South San Francisco: Exelixis; Inc; 2016.
13. Cabometyx® (cabozantinib) [summary of product characteristics]. Available from: http://www.eea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information-human/004163/WC500214071.pdf. Accessed March 3, 2017.
14. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999;19(9):5902–5912.
15. Nakagawa N, Yao M, Baba M, et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 2006;66(7):3699–3705.
16. Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIP promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;111(37):13373–13378.
17. Yu H, Liu R, Ma B, et al. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer. 2015;113(4):616–625.
18. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 2007;212(2):316–325.
19. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
20. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib in renal cell carcinoma. Oncogene. 2016;35(21):2687–2697.
21. Cometriq® (cabozantinib) [prescribing information]. South San Francisco: Exelixis, Inc; 2012.
22. Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56(5):477–491.
23. European Medicines Agency. CHMP assessment report: Cabometyx. 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004163/WC500214070.pdf. Accessed January 20, 2017.
24. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104(2):93–113.
25. Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs. 2012;30(5):2066–2079.
26. Ravaud A. Editorial comment to Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. Int J Urol. 2012;19(9):805.
27. Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125–134.
28. Ruiz JN, Belum VR, Creel P, Cohn A, Ewer M, Lacouture ME. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. Curr Genitourin Cancer. 2014;12(5):341–347.
29. Miles D, Junhe NL, Lacy S, Nguyen L. Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis. Clin Pharmacokinet. 2016;55(1):93–105.
30. Exelixis. CABOMETYX dosing and administration guide. 2016. Available from: https://hcp.cabometyx.com/downloads/CABOMET XDosingandAdministrationGuide.pdf. Accessed February 16, 2017.
31. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Washington: US Department of Health and Human Services; 2017.
32. Hurria A, Dotan E, Baumgartner J, et al. NCCN guidelines: older adult oncology —version 2. 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed February 22, 2017.
33. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16 Suppl 2:32–44.
34. Kollmannsberger C, Bjarnason G, Burnett P, et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist. 2011;16(5):543–553.
35. Nguyen L, Holland J, Mamlok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–1302.
36. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823.
37. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900–908.
38. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159(3):185–194.
39. Pickering TG, White WB, Giles TD, et al. When and how to use self and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4(2):96–110.
40. Kollmannsberger C, Feldman RD, et al. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol. 2012;19(4):202–208.
43. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.

44. Ivaniy P, Beutel G, Drewes N, et al. Therapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinib. Clin Genitourin Cancer. 2017;15(2):280–290.

45. Cho YT, Chan CC. Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway. Eur J Dermatol. 2013;23(2):274–275.

46. Esfandiari NH, Hesselte EA. Visual vignette: cabozantinib-induced hand-foot syndrome. Endocr Pract. 2013;19(6):1071.

47. Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multit kinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2016;41(1):8–15.

48. Zuo RC, Apolo AB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151(2):170–177.

49. Jayaram A, Zafeiriou Z, de Bonos JS. Cabozantinib: getting under the skin of cutaneous toxicity. JAMA Oncol. 2015;1(4):535–536.

50. Polovich PO, LeFebvre KB. Side effects of cancer therapy. In: Polovich PO, Olsen M, LeFebvre KB, editors. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 4th ed. Pittsburgh: Oncology Nursing Society; 2016:171–435.

51. Edmonds K, Hull D, Spencer-Shaw A, et al. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs. 2012;16(2):172–184.

52. Oncology Nursing Society. PEP rating system overview. 2016. Available from: https://www.ons.org/practice-resources/pep. Accessed February 16, 2017.

53. Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care. 2013;7(2):162–167.

54. American Cancer Society. Nutrition for the person with cancer during treatment. 2017. Available from: https://www.cancer.org/treatment/management-of-gastroesophageal-reflux-disease.html. Accessed February 16, 2017.

55. Ryan KP. Symptom control and side effects. In: When Tumor is the Rumor and Cancer is the Answer. Bloomingon (IN): AuthorHouse; 2013:181–209.

56. Cancer Research UK. Tips on coping with diarrhoea. Available from: http://www.cancerresearchuk.org/about-cancer/coping/physically/bowel-problems/types/diarrhoea/tips-coping-diarrhoea. Accessed August 24, 2017.

57. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neuregulin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17–24.

58. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neuregulin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–4119.

59. Ettinger D, Berger M, Aston J. NCCN guidelines: antiemesis – version 2. 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed February 16, 2017.

60. Cesamet® (nabilone) [prescribing information]. Somerset (NJ): Meda Pharmaceuticals Inc; 2013.

61. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastrosophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–329.
